

# NEET SS ANESTHESIA

*Updated Notes 2026*



## CRITICAL CARE PART-2



## **Instructions**

- The notes must be used in conjunction with the Marrow Programme for Anaesthesia Residents videos and should not be considered standalone material.

## **Please note:**

- The information in this book has been printed based on the transcript of the Marrow Programme for Anaesthesia Residents videos.
- The information contained in this book is for educational purposes only. The content provided is not intended to substitute for professional medical advice, diagnosis or treatment.
- This book cannot be sold separately. It has been made available to only select eligible users who have an active subscription to Marrow Programme for Anaesthesia Residents videos.
- The text, images, slides, and other materials used in this book have been contributed by the faculty, who are subject matter experts. We have merely reproduced them as video transcripts in this book.
- The notes have been consciously designed in a way that is concise and revisable. To ensure this, we have intentionally added only the most relevant modules and images that are needed for you.
- Reasonable care has been taken to ensure the accuracy of the information provided in this book. Neither the faculty nor Marrow takes any responsibility for any liability or damages resulting from applying the information provided in this book.
- This set contains notes of all main videos published in the app until March 2026. You can find notes for any additional videos published after this date within the app under the videos section.

## **All Rights Reserved**

No part of this publication shall be reproduced, copied, transmitted, adapted, modified or stored in any form or by any means, electronic, photocopying, recording or otherwise.

© Marrow

//ME841SS-PPL

# Contents

## Volume - 1

### Basics of Critical Care Medicine

1.	Hemodynamic Monitoring : I	1
2.	Central Venous Line & CVP Measurement	17
3.	Cardiac Output Monitoring	25
4.	Assessing Fluid Responsiveness in the ICU	43
5.	Assessing Adequacy of Oxygen Delivery	55

### Mechanical Ventilation

6.	Basics of Mechanical ventilation	69
7.	Ventilator Graphics and Basic Modes of Mechanical Ventilation	78
8.	Patient Ventilator Asynchrony	90
9.	Weaning from Mechanical Ventilation	108
10.	Advanced Modes of Mechanical Ventilation	129

### Respiratory Disorders

11.	Acute Respiratory Distress Syndrome : Part I	146
12.	Acute Respiratory Distress Syndrome : Part II	162
13.	Pulmonary Embolism	169
14.	COPD and Asthma	192
15.	Respiratory Management in Specific Clinical Scenarios : Part I	208
16.	Respiratory Management in Specific Clinical Scenarios : Part II	224
17.	PA Catheter	237
18.	Pleural disorder in ICU	247

## **Electrolyte and Acid Base Disorders**

19. Interpreting ABG	271
20. Sodium Disorders In The ICU	283
21. Potassium Disorders in the ICU	298
22. Disorders of Calcium, Magnesium & Phosphorus Metabolism	305

## **Shock**

23. Sepsis & Septic Shock : Evaluation & Management	323
24. Organ Dysfunction in Sepsis	339
25. Cardiogenic Shock : Part I	359
26. Cardiogenic Shock : Part II	371
27. Extracorporeal Therapies In Sepsis	377

## **Cardiac Critical Care**

28. Basic Echocardiography	385
29. Aortic Dissection	399
30. Right Ventricular Failure in ICU	410
31. Post Cardiac Arrest Management & Prognostication	424
32. Pericarditis and myocarditis	440
33. BLS and ACLS	464
34. ICU Management of ACS : Part I	482
35. ICU Management of ACS : Part II	502
36. 2025 ACC/AHA CPR Guidelines : Updates	529

## **Infections**

37. Ventilator Associated Pneumonia (VAP)	537
38. Community Acquired Pneumonia (CAP)	552
39. Infections in Immunocompromised Host	567
40. Managing MDR Gram Negative Infections : Part I	590

41. Managing MDR Gram Negative Infections : Part II	599
42. Interpreting Antibiogram & MIC	602
43. CNS Infections in ICU	611
44. Leptospirosis & Rickettsial diseases	630
45. Dengue Fever	647

### **Endocrine disorders**

46. Glucose Control in ICU	659
47. Endocrine Emergencies	675

## **Volume - 2**

### **Renal Disorders**

48. Acute Kidney Injury : Part I	691
49. Acute Kidney Injury : Part II	699
50. Renal Replacement Therapy : Part I	716
51. Renal Replacement Therapy : Part II	726

### **Hematology**

52. Hematological Emergencies in Critical Illness	741
53. Thrombocytopenia in the ICU	754

### **Gastrointestinal & Hepatological Disorders**

54. Abdomen in the ICU	765
55. Acute Liver Failure	774
56. ACLF in ICU	802
57. Decompensated CLD	817
58. Acute Pancreatitis	844
59. Acute Mesentric Ischemia	856
60. Intra-abdominal Hypertension and Abdominal Compartment Syndrome	867
61. Clostridioides Difficile Colitis	873

## **Neurological Disorders**

62. Traumatic Brain Injury	886
63. ICU Management of Traumatic Brain Injury	898
64. ICP Monitoring	908
65. Intracranial Haemorrhage	921
66. Subarachnoid Haemorrhage	935
67. Neuromuscular disorders in ICU : Part I	949
68. Neuromuscular disorders in ICU : Part II	957
69. Delirium in the ICU & PADIS Guidelines	971

## **Special Topics**

70. Management of Brain Dead Organ Donors	986
71. Nutrition in the ICU	1004
72. Pharmacokinetics	1012
73. Haemodynamic Management and Pharmacotherapy in Acute Polytrauma	1027
74. End of Life Care in the ICU	1048

## **ECMO**

75. ECMO - Basics	1064
76. Managing a patient on ECMO	1083

## **Toxicology**

77. General Approach to Poisoning	1109
78. Acetaminophen Toxicity	1119
79. Pesticides	1129
80. Management of Snake Bites	1142
81. Recreational Drug Toxicity	1154

## **Miscellaneous**

82.	Important Clinical Trials in Critical Care	1166
83.	Catheter Related Blood Stream Infection	1189
84.	Obstetric Critical Care : General Consideration	1205
85.	Obstetric Critical Care : Pregnancy Specific	1214
86.	Management Of Burn Patient In ICU	1227
87.	Novel Chemo and Toxicity in ICU	1237



# ACUTE KIDNEY INJURY : PART I

----- Active space -----

## Background

00:01:28

- 1802 : William Heberden → Described acute kidney injury as Ischuria Renalis.
- 2004 : Bellomo et al → AKI (RIFLE criteria).
- AKIN criteria (2007).
- KDIGO criteria (2012).
- Acute kidney injury (AKI) : Syndrome characterized by a rapid deterioration of kidney function occurring within hours or days.

## Classification :

- RIFLE : ADQI Group, 2004.
- AKIN : AKIN Network, 2007.
- KDIGO : KDIGO Group, 2012.

	RIFLE	AKIN	KDIGO
<b>Diagnostic criteria</b>		Increase in serum creatinine of $\geq 0.3$ mg/dL or $\geq 50\%$ within 48 hours OR Urine output of $< 0.5$ mL/kg/hour for $> 8$ hours	Increase in serum creatinine of $\geq 0.3$ mg/dL within 48 hours or $\geq 50\%$ within 7 days OR Urine output of $< 0.5$ mL/kg/hour for $> 8$ hours
<b>Staging criteria</b>			
Risk (RIFLE) or stage 1 (AKIN/KDIGO)	Increase in serum creatinine of 50 to 99% OR Urine output of $< 0.5$ mL/kg/hour for 6 to 12 hours	Increase in serum creatinine of $\geq 0.3$ mg/dL or 50 to 100% OR Urine output of $< 0.5$ mL/kg/hour for 6 to 12 hours	Increase in serum creatinine of $\geq 0.3$ mg/dL or 50 to 99% OR Urine output of $< 0.5$ mL/kg/hour for 6 to 12 hours
Injury (RIFLE) or stage 2 (AKIN/KDIGO)	Increase in serum creatinine of 100 to 199% OR Urine output of $< 0.5$ mL/kg/hour for 12 to 24 hours	Increase in serum creatinine of $> 100$ to 200% OR Urine output of $< 0.5$ mL/kg/hour for 12 to 24 hours	Increase in serum creatinine of 100 to 199% OR Urine output of $< 0.5$ mL/kg/hour for 12 to 24 hours
Failure (RIFLE) or stage 3 (AKIN/KDIGO)	Increase in serum creatinine of $\geq 200\%$ OR Increase in serum creatinine by $> 0.5$ mg/dL to $> 4.0$ mg/dL. OR Urine output of $< 0.3$ mL/kg/hour for $> 24$ hours or anuria for $> 12$ hours OR Initiation of renal replacement therapy	Increase in serum creatinine of $> 200\%$ OR Increase in serum creatinine by $> 0.5$ mg/dL to $\geq 4.0$ mg/dL. OR Urine output of $< 0.3$ mL/kg/hour for $> 24$ hours or anuria for $> 12$ hours OR Initiation of renal replacement therapy	Increase in serum creatinine of $\geq 200\%$ OR Increase in serum of $\geq 0.3$ mg/dL to $\geq 4.0$ mg/dL. OR Urine output of $< 0.3$ mL/kg/hour for $\geq 24$ hours or anuria for $\geq 12$ hours OR Initiation of renal replacement therapy
Loss (RIFLE)	Need for renal replacement therapy for $> 4$ weeks		
End stage (RIFLE)	Need for renal replacement therapy for $> 3$ months		

## KDIGO definition of acute kidney injury :

Stage	Creatinine criteria	Urine output criteria
1	Cr 1.5-1.9 times baseline, OR Cr increase $> 0.3$ mg/dL	$< 0.5$ mL/kg/hr $\times$ 8-12 hours
2	Cr 2-2.9x baseline	$< 0.5$ mL/kg/hr for $> 12$ hours
3	Cr $> 3x$ baseline, OR Cr $> 4$ mg/dL, OR Initiation of dialysis	$< 0.3$ mL/kg/hr for $> 24$ hours, OR Anuria $> 12$ hours

Patients are staged based on the single most concerning feature.


----- Active space -----

Pitfalls :

Shortcoming	Potential solution
1. Inability of S. Creat to detect changes at high GFR level	1. Sequential creatinine clearances (e.g, with urine collections of 2-8 h)
2. S. Creat is a late marker of decreased GFR	2. Biomarkers of kidney damage/cystatin C/more frequent measurement of S. Creat
3. Critical illness may confound diagnosis by creatinine criteria	3. Correction of S. Creat for fluid balance/cystatin C
4. Requirement for baseline S. Creat with different methods to handle missing baseline	4. Thorough search for baseline/reporting applied method in literature
5. S. Creat is a measure of function not of tissue damage and may miss subclinical AKI	5. Combining S. Creat with biomarkers of kidney damage
6. Urine output criteria are less frequently used, lack specificity, and may be too liberal	6. Consistent use of urine output criteria and definition of more stringent criteria
7. KDIGO definition does not provide insight into pathophysiology	7. Use of biomarkers that reflect different pathophysiological mechanisms
8. Absence of gold standard	8. No solution for the time being
9. Different criteria for similar stage may have different association with outcome	9. Consensus criteria for RRT initiation/detailed description of AKI criteria
10. KDIGO definition is unreliable for assessment of renal recovery	10. Use of cystatin C/assesses recovery by S. Creat after a sufficient time from critical illness (ie, after correction of sarcopenia and fluid overload)


AKI Spectrum

00:12:27



- Early recovery : S.creatinine/ urine output returning to baseline < 7 days.
- Rapid recovery : S.Cr / urine output returning to baseline < 48 hours.
- AKI :
  - worse 1 year outcomes.
  - Recurrence of AKI.

AKI, AKD,CKD :




**Incidence of AKI :**

Incidence timing and outcome of AKI in critically ill patients.

- AKI incidence :
  - 35% : RIFLE.
  - 38% : AKIN.
  - 10-15% of AKI patients in ICU require renal replacement therapy (RRT).
- 38% : KDIGO.

----- Active space -----

**Acute kidney injury → short term and long term effects :**



- CKD : (14-20)%.
- Dialysis : (5-7)%.
- Coronary events : (10.3- 19.8)/1000 person year.
- mortality : (30-40)%.

**Risk factors for developing AKI in the ICU :**

Non modifiable	modifiable Risk factor
<ul style="list-style-type: none"> <li>• Older age.</li> <li>• Gender.</li> <li>• Ethnicity.</li> <li>• Comorbidity :                             <ul style="list-style-type: none"> <li>• Hypertension.</li> <li>• Diabetes mellitus.</li> <li>• Chronic kidney disease.</li> <li>• Heart failure.</li> <li>• CAD &amp; PAD.</li> <li>• COPD.</li> <li>• Obesity.</li> <li>• malignancy.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Hypovolaemia.</li> <li>• Sepsis.</li> <li>• Choice of fluid.</li> <li>• Nephrotoxins.</li> <li>• major surgery.</li> <li>• Trauma, including burn patients.</li> <li>• Critical illness.</li> <li>• Anemia.</li> <li>• Emergency procedures.</li> <li>• Radiologic Contrast media.</li> <li>• COVID-19.</li> </ul>

--- Active space ---

**Causes of AKI**

00:23:23

1. Prerenal : Sudden and severe reduction in blood pressure (shock) of interruption of blood flow to the kidneys from severe injury or illness.


- Blood loss.
- Dehydration.
- Heart failure.
- Sepsis.
- Vascular occlusion.

2. Intrinsic Renal : Direct injury to the kidneys by inflammation, drugs, toxins, infection, or reduced blood supply.


- Acute tubular necrosis :
  - Drugs.
  - Toxins.
  - Prolonged hypotension.
- Glomerulonephritis
- Acute tubular necrosis :
  - Drugs.
  - Toxins.
  - Autoimmune disease..
  - Infection.
- Small-vessel vasculitis.

3. Postrenal : Sudden obstruction of urine flow due to enlarged prostate, kidney stones, bladder injury or tumor.

- Benign prostatic hyperplasia.
- Cervical cancer.
- meatal stenosis/phimosis.
- Retroperitoneal fibrosis.
- Prostate cancer.
- Urinary calculi.

**BEST study :**


- 6647 patients in ICU.
- 19.2% developed AKI.



AKI by Aetiology in BEST Kidney Study

Pathology of AKI in the ICU :

----- Active space -----




Septic AKI

00:29:34


- Syndrome characterized by presence of sepsis and AKI definition.
- Incidence : >40% patient develop AKI.
- RRT: 30%.
- mortality : 40%.
- Attributable mortality : 10%.

Pathophysiology of septic AKI :



----- Active space -----

### Effect on GFR :



### Contrast Assoc AKI (CA-AKI) :

- Rise in SCr  $\geq 0.5$  mg/dl (44mmol/D) or a 25% increase from baseline value, assessed at 48 hours after a radiological procedure.
- mechanism :
  - Direct tubular toxicity.
  - Intra renal vasoconstriction.
- Incidence :
  - Normal patients : 1-2%.
  - Patients with risk factors : upto 25%.
    - Pre existing renal dysfunction.
    - Diabetes.
    - LV dysfunction.
    - Concurrent nephrotoxic medications.
  - 3.3% (if SCr > 0.5mg/dl).
  - 10.2% (if SCr > 25% baseline).
  - 10.5% (if GFR < 25% baseline).

### Retrospective study :

Incidence & outcome of contrast-associated acute kidney injury assessed with (RIFLE) criteria in critically ill patients of medical & surgical intensive care units :

- Incidence of CI-AKI was 15.5%.
- 55.8% had pre-existing kidney injury.
- CA-AKI patients were divided into risk (31%), injury (31%), and failure (38%).
- Dialysis : 7% patient.

- Recovery rate of AKI was 17% at the time of hospital discharge.
- Higher APACHE II scores were associated with a higher risk of CA-AKI.

----- Active space -----

**Risk factors :**

Definite	Conflicting
<ul style="list-style-type: none"> <li>• Pre-existing Kidney disease</li> <li>• Diabetes, hypertension, CHF</li> <li>• Advanced age</li> <li>• Volume depletion</li> <li>• Hemodynamic instability</li> <li>• Nephrotoxic medications</li> <li>• Large volume or high osmolality contrast agent</li> </ul>	<ul style="list-style-type: none"> <li>• ACE-I and ARBs</li> <li>• Renal transplantation</li> <li>• Multiple myeloma</li> <li>• Female</li> <li>• Cirrhosis</li> </ul>

**Prediction of CI-AKI after PCImehran risk model, JACC,2004 :**

Risk factors	Integer score (calculate)
Hypotension	5
IABP	5
CHF	5
Age > 75 years	4
Anemia	3
Diabetes	3
Contrast-media volume	1 per 100 ml
SCr > 1.5 mg/dl (> 132.6 μmol/l) or eGFR < 60 ml/min per 1.73 m <sup>2</sup>	4 2 for 40-60 4 for 20-39 6 for <20

Note: Low risk: cumulative score < 5; High risk: cumulative score > 16.

7.5% for low [<5] and 57.3% for high [>16]

**Preventive measures :**

- Reduced dose of contrast medium.
- Isotonic saline.
- Isotonic bicarbonate solution.
- NAC.
- Diuretics.
- Statins.
- Theophylline.
- Fenoldopam.

} No role

**Contrast medium :**

- Dose : < 100 ml.
- Gms of iodine/eGFR (<1=3%, >1%= 25%),
- maximum dose : (5gm/kg) / SCr,
- Route : IV preferred over arterial.

---- Active space ----

Ionicity	Osmolality mosm/kg H <sub>2</sub> O	Relative Osmolality	Examples
Ionic monomer	1500-1900	High	Diatrizoate, iothalamate
Ionic dimer	600	Low	Ioxaglate
Nonionic monomer	500-700	Low	Iohexol, iopamidol, iomeprol
Nonionic dimer	290-320	Iso	Iodixanol, iotrolan

**Saline :**

- NS preferred over 45% DNS.
- 1 hr before & upto 6 hrs after administration.
- At least 100ml/hr urine output.
- Rate : (1-2)ml/kg/hr infusion.

**NaHCO<sub>3</sub> :**

- Isotonic solution of NaHCO<sub>3</sub> : 850 cc of D5 + 150 cc of 8.4 % NaHCO<sub>3</sub>.

**NAC :**


- Controversial benefit.
- Oral route preferred : Tolerable and inexpensive.
- ACC/AHA guidelines do not recommend.
- KDIGO : Suggest oral administration.
- Low dose : 600 mg bd for 2 days.

**Preserve trial :**

- Comparison of NS, NaHCO<sub>3</sub>, NAC & Placebo.
- Result : No outcome benefits.

**Effectiveness of Prevention Strategies for Contrast-Induced Nephropathy :**

Pooled group	Studies, n	Pooled RR for CIN (95% CI)
High-dose NAC	18	0.78 (0.59-1.03)
IA administration	18	0.78 (0.66-1.12)
IV administration	2	0.55 (0.12-2.62)
Low-dose NAC	36	0.75 (0.63-0.88)
IA administration	30	0.77 (0.66-0.91)
IV administration	5	0.62 (0.18-2.10)
Oral NAC	40	0.77 (0.65-0.92)
IV NAC	14	0.90 (0.72-1.12)
NAC when LOCM are used	40	0.69 (0.58-0.84)
NAC when IOCM are used	7	1.12 (0.74-1.69)



CIN - Contrast-induced nephropathy  
 IA - Intra-arterial  
 IOCM - Iso-osmolar contrast media  
 IV - Intravenous

LOCM - Low-osmolar contrast media  
 NAC - N-acetylcysteine  
 RR - Risk ratio

## ACUTE KIDNEY INJURY : PART II

----- Active space -----

### Diagnosis of AKI

00:00:22

#### History & examination :

##### History :


- GI loss : vomiting, diarrhoea, haemorrhage.
- Decreased intake.
- Heart failure, hypotension.
- Procedures (Surgery, angioplasty).
- Systemic conditions (DM, HTN, IHD, PAD, jaundice).
- Infection.
- Blood in urine.
- Exposure drugs :
  - i. Antibiotic exposure.
  - ii. Immunosuppressive therapy (Transplant, malignancy).
  - iii. Radiocontrast agent.
  - iv. Herbal medicine, recreational drugs.
  - v. Flank pain, anuria, hematuria.

##### Examination :

- Fluid status : mucous membrane, skin turgor, sunken eyes, orthostatic hypotension.
- CNS : Stroke, neuropathy (vasculitis).
- Heart : S3, gallop, arrhythmias, murmur, raised JVP.
- Abdomen : Compartment syndrome, bruit mass, distended bladder, palpable tender kidney.
- Extremities : Peripheral pulses (PAD), rash (vasculitis).
- Rectal and pelvic examination.

--- Active space ---

## Diagnostic work-up for AKI in ICU :



## Urine analysis :

- Reagent/dipstick analysis.
- microscopic analysis.

## Dipstick analysis :

- Qualitative & easy to interpret.
- Quick bedside assessment.
- Eosinophils : Acute interstitial nephritis.
- Leukocytes/pus cells : Pyelonephritis.



urine dipstick

pH	<ul style="list-style-type: none"> <li>Normal range : 4.0 to 7.8</li> <li>Acidic : UTI</li> <li>Alkaline : Infection with urea splitting organisms, diuretic therapy, nasogastric suction.</li> </ul>
Hemoglobin	<ul style="list-style-type: none"> <li>RBC &amp; Hb : Glomerulonephritis.</li> <li>Hb : Intravascular hemolysis or rhabdomyolysis.</li> </ul>
Protein	<ul style="list-style-type: none"> <li>Detect only albumin.</li> <li>Physiological : 150 mg/d.</li> <li>Microalbuminuria : 30-300 mg/d (Not detected).</li> <li>Nephrotic range : &gt;3 g/d (Glomerulonephritis).</li> <li>Tubular range : 1-2 g/d (Acute tubular necrosis).</li> <li>Gammopathies : Globulin (Not detected).</li> </ul>
Osmolality	<ul style="list-style-type: none"> <li>Normal : 500-800 mOsm/kg.</li> <li>Increased : SIADH, pre renal AKI.</li> <li>Decreased : DI, polydipsia, renal AKI.</li> </ul>
Specific gravity	<ul style="list-style-type: none"> <li>Normal : 1.003 to 1.030</li> <li>Increased : Pre renal AKI, glycosuria, SIADH.</li> <li>Decreased : Renal AKI, DI, ATN, GN.</li> </ul>
Glucose	<ul style="list-style-type: none"> <li>Renal threshold : 160-180 mg/dl.</li> </ul>
Ketones	<ul style="list-style-type: none"> <li>Diabetic &amp; starvation ketosis.</li> <li>False positive : Sulphydryl groups, e.g. Captopril.</li> </ul>
Leukocyte esterase	<ul style="list-style-type: none"> <li>Dipstick is sensitive for leucocytes even after lysis.</li> <li>UTI</li> </ul>
Nitrites	<ul style="list-style-type: none"> <li>Bacteria convert nitrates to nitrites.</li> <li>False negatives : Alkaline urine.</li> </ul>

----- Active space -----

## Microscopic examination :

- Red blood cells (RBCs).
- White blood cells (WBCs).
- Epithelial cells.
- Bacteria, yeast and parasites.
- Trichomonas.
- Crystals.
- Electrolytes.
- Casts & sediments.

## Electrolytes :

- Spot urine Na :
  - Urine Na <10 mmol/L = Pre-renal.
  - Urine Na >40 mmol/L = Renal.
- Fractional excretion of Na (FeNa) =  $\frac{\text{Urine Na} \times \text{Plasma creatinine}}{\text{Plasma sodium} \times \text{Urine creatinine}}$ 
  - FeNa <0.01 (<1%) : Pre-renal.
  - FeNa >0.03 (3%) : Renal or post-renal.
  - FeNa 1-2% : Indeterminate significance.